Bob brings an extensive history of innovation in the cell and gene therapy industry, experience developing and managing global business operations, and leadership honed through driving growth in several regenerative medicine organizations. In 1999, Bob co-founded what is now known as Minaris Regenerative Medicine, formerly Hitachi Chemical Advanced Therapeutics Solutions’ (HCATS, formerly PCT) — the first CDMO exclusively focused on the emerging cell and gene therapy industry. As its president and CEO, he oversaw its successful growth and development strategy over the last two decades.
Bob began his career as an educator and has been active in the public health arena. He has served as treasurer and founding member of International Society for Cellular Therapy, director for the Association for the Advancement of Blood & Biotherapies, and chairman for the Alliance for Regenerative Medicine, where he previously served as director, vice chairman, and co-chair of the Standards and Technology Committee. He has published and presented extensively on a variety of topics relating to cellular therapies.
Dr. Carlson is interested in the future role of biology as a human technology and is a founder of Biodesic, a consulting firm at the juncture of biology and other disciplines such as marketing, engineering, and investment. He is a serial entrepreneur and has worked to develop new biological technologies in both academic and commercial environments, focusing on molecular measurement and microfluidic systems. He has also developed and published a number of novel metrics for quantifying the impact and progress of biological technologies. Carlson is the author of the book Biology is Technology: The Promise, Peril, and New Business of Engineering Life, published in 2010 by Harvard University Press. Dr. Carlson earned a doctorate in Physics from Princeton University in 1997. LinkedIn
Daniella Kranjac is Co-Founder and Managing Partner of Dynamk Capital and has been building life sciences businesses and developing and commercializing life sciences products for 20 years. Having co-founded Wave Biotech LLC, she and a partner drove the start-up, growth, and commercialization of highly disruptive technology. As Vice President of the organization, Daniella established high growth with significant brand recognition and led the group to a successful exit and acquisition by GE Healthcare in 2007.
At GE Healthcare, Daniella held a variety of strategic, M&A, and business development roles. One of her most notable achievements is the success in an entrepreneurial group within GE Healthcare, where integrating the acquired Xcellerex business enabled global commercialization of a several hundred million dollar enterprise solutions business. Her extensive business development, negotiation, and deal-making experience with multinational biopharma and governments in developed and emerging markets provide a broad network of colleagues, customers, innovators, and key opinion leaders.
Tim Kelly, Ph.D., is CEO of RoosterBio, Inc. and prior to that served as President of Manufacturing at Asklepios Biopharmaceutical, Inc. He has overseen development and manufacturing services for over 325 biologics at all stages of development and commercialization and has supported numerous successful FDA and international regulatory inspections throughout his career. Read Full Bio
Founder and Chief Product Officer of RoosterBio Inc., Dr. Jon A. Rowley, started RoosterBio in 2013 as part of his personal quest of having the biggest impact possible on the commercial translation of technologies that incorporate living cells, including cellular therapies, engineered tissues, and tomorrow’s medical devices. Read Full Bio